Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells

Abstract

Aim: The therapeutic targeting of the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) death receptors in cancer, including non-small cell lung cancer (NSCLC), is a widely studied approach for tumor selective apoptotic cell death therapy. However, apoptosis resistance is often encountered. The main aim of this study was to investigate the apoptotic mechanism underlying TRAIL sensitivity in three bortezomib (BTZ)-resistant NSCLC variants, combining induction of both the intrinsic and extrinsic pathways.

Methods: Sensitivity to TRAIL in BTZ-resistant variants was determined using a tetrazolium (MTT) and a clonogenic assay. A RT-qPCR profiling mRNA array was used to determine apoptosis pathway-specific gene expression. The expression of these proteins was determined through ELISA assays and western Blotting, while apoptosis (sub-G1) and cytokine expression were determined using flow cytometry. Apoptotic genes were silenced by specific siRNAs. Lipid rafts were isolated with fractional ultracentrifugation.

Results: A549BTZR (BTZ-resistant) cells were sensitive to TRAIL in contrast to parental A549 cells, which are resistant to TRAIL. TRAIL-sensitive H460 cells remained equally sensitive for TRAIL as H460BTZR. In A549BTZR cells, we identified an increased mRNA expression of TNFRSF11B [osteoprotegerin (OPG)] and caspase-1, -4 and -5 mRNAs involved in cytokine activation and immunogenic cell death. Although the OPG, interleukin-6 (IL-6), and interleukin-8 (IL-8) protein levels were markedly enhanced (122-, 103-, and 11-fold, respectively) in the A549BTZR cells, this was not sufficient to trigger TRAIL-induced apoptosis in the parental A549 cells. Regarding the extrinsic apoptotic pathway, the A549BTZR cells showed TRAIL-R1-dependent TRAIL sensitivity. The shift of TRAIL-R1 from non-lipid into lipid rafts enhanced TRAIL-induced apoptosis. In the intrinsic apoptotic pathway, a strong increase in the mRNA and protein levels of the anti-apoptotic myeloid leukemia cell differentiation protein (Mcl-1) and B-cell leukemia/lymphoma 2 (Bcl-2) was found, whereas the B-cell lymphoma-extra large (Bcl-xL) expression was reduced. However, the stable overexpression of Bcl-xL in the A549BTZR cells did not reverse the TRAIL sensitivity in the A549BTZR cells, but silencing of the BH3 Interacting Domain Death Agonist (BID) protein demonstrated the importance of the intrinsic apoptotic pathway, regardless of Bcl-xL.

Conclusion: In summary, increased sensitivity to TRAIL-R1 seems predominantly related to the relocalization into lipid rafts and increased extrinsic and intrinsic apoptotic pathways.

Keywords

TRAIL / bortezomib / resistance / sensitization / Bcl-2 family / lipid rafts / cytokines

References

[1] Niemira M,Szalkowska A.Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: identification of key modules and genes by weighted gene co-expression network analysis (WGCNA).Cancers2019;12:37 PMCID:PMC7017323

[2] Testa U,Pelosi E.Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells.Cancers2018;10:248 PMCID:PMC6116004

[3] Spira A.Multidisciplinary management of lung cancer.N Engl J Med2004;350:379-92

[4] van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours.Open Biol2018;8:180037 PMCID:PMC6030119

[5] Gotwals P,Cipolletta D.Prospects for combining targeted and conventional cancer therapy with immunotherapy.Nat Rev Cancer2017;17:286-301

[6] Das S,Singh SS,Shrivastava R.Mechanism of interaction between autophagy and apoptosis in cancer.Apoptosis2021;26:512-33

[7] Singh R,Sarosiek K.Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.Nat Rev Mol Cell Biol2019;20:175-93 PMCID:PMC7325303

[8] Snajdauf M,Vachtenheim J Jr.The TRAIL in the treatment of human cancer: an update on clinical trials.Front Mol Biosci2021;8:628332 PMCID:PMC8006409

[9] Singh D,Singh S.Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.Future Oncol2021;17:581-96

[10] Carneiro BA.Targeting apoptosis in cancer therapy.Nat Rev Clin Oncol2020;17:395-417 PMCID:PMC8211386

[11] de Looff M, de Jong S, Kruyt FAE. Multiple interactions between cancer cells and the tumor microenvironment modulate TRAIL signaling: implications for TRAIL receptor targeted therapy.Front Immunol2019;10:1530 PMCID:PMC6617985

[12] Herbst RS,Kurzrock R.Phase I Dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.J Clin Oncol2010;28:2839-46

[13] Cheah CY,Fanale MA.Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.Lancet Haematol2015;2:e166-74

[14] Ouyang X,Jie F.Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.Invest New Drugs2018;36:315-22

[15] Soria JC,Zatloukal P.Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.J Clin Oncol2011;29:4442-51

[16] Oh YT.Regulation of cancer metastasis by TRAIL/death receptor signaling.Biomolecules2021;11:499 PMCID:PMC8065657

[17] Kaur I,Sachdeva M,Venkatachalam T.Exploring the mitochondrial apoptotic cell death landscape and associated components serving as molecular targets, primarily for synthetic and natural drugs targeting oncology therapeutics.Curr Mol Pharmacol2021;14:1066-82

[18] Stegehuis JH,de Vries EG,de Jong S.TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.Drug Resist Updat2010;13:2-15

[19] Kruyt FA.TRAIL and cancer therapy.Cancer Lett2008;263:14-25

[20] Borghi A,Beyaert R.TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death.Biochem Pharmacol2016;116:1-10

[21] Greenlee JD,Ortiz-Otero N.Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization.Elife2021;10:e67750 PMCID:PMC8331188

[22] Ouyang W,Liu Y.Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.Int J Oncol2011;39:1577-86

[23] Song JH,Bellail A.Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.Cancer Res2007;67:6946-55

[24] Xu L,Luo Y.Epirubicin enhances TRAIL-induced apoptosis in gastric cancer cells by promoting death receptor clustering in lipid rafts.Mol Med Rep2011;4:407-11

[25] You C,Sun Y.β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors.Int J Oncol2018;53:2258-68

[26] Fisher MJ,Wu L.Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.Clin cancer Res2001;7:1688-97

[27] Lee SH,Kim HS.Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.Cancer Res1999;59:5683-6

[28] Wagner KW,Januario T.Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.Nat Med2007;13:1070-7

[29] Frese S,Gugger M,Schmid RA.Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.J Thorac Cardiovasc Surg2002;123:168-74

[30] Zanca C,Quintavalle C.PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer.J Cell Mol Med2008;12:2416-26 PMCID:PMC4514119

[31] Mei Y,Xie W,Li M.Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis.Neoplasia2007;9:871-81 PMCID:PMC2040214

[32] Voortman J,Abou El Hassan MA,Kruyt FA.TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.Mol Cancer Ther2007;6:2103-12

[33] Manasanch EE.Proteasome inhibitors in cancer therapy.Nat Rev Clin Oncol2017;14:417-33 PMCID:PMC5828026

[34] Orlowski RZ.Proteasome inhibitors in cancer therapy: lessons from the first decade.Clin Cancer Res2008;14:1649-57

[35] Scagliotti G.Proteasome inhibitors in lung cancer.Crit Rev Oncol Hematol2006;58:177-89

[36] de Wilt LH, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FA. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?.Crit Rev Oncol Hematol2013;85:363-72

[37] de Wilt LH,Assaraf YG.Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.Biochem Pharmacol2012;83:207-17

[38] Ferreira CG,Peters GJ,Giaccone G.Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.Cancer Res2000;60:7133-41

[39] Ashkenazi A,Fong S.Safety and antitumor activity of recombinant soluble Apo2 ligand.J Clin Invest1999;104:155-62 PMCID:PMC408479

[40] Reis CR,Natoni A.Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Cell Death Dis2010;1:e83 PMCID:PMC3035906

[41] van der Sloot AM,Szegezdi E.Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.Proc Natl Acad Sci U S A2006;103:8634-9 PMCID:PMC1482632

[42] Cao L.Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications.Pharmacol Res2021;163:105297 PMCID:PMC7962892

[43] Franken NAP,Stap J,van Bree C.Clonogenic assay of cells in vitro.Nat Protoc2006;1:2315-9

[44] Cillessen SAGM,Ossenkoppele GJ.Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.Br J Haematol2006;134:283-93

[45] Bijnsdorp IV,Gokoel S,Peters GJ.Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.Cancer Sci2008;99:2302-8

[46] Zheng D,Elinav E.Inflammasome activation and regulation: toward a better understanding of complex mechanisms.Cell Discov2020;6:36 PMCID:PMC7280307

[47] Rachner TD,Rauner M.Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.J Cell Biochem2009;108:106-16

[48] Zinonos I,Lee M.Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.J Bone Miner Res2011;26:630-43 PMCID:PMC5568243

[49] Soto-Gamez A,Zhou X,Quax W.Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.Cancer Lett2022;525:67-75

[50] Lane D,Laplante C,Rancourt C.Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.J Ovarian Res2013;6:82 PMCID:PMC3874685

[51] Yazdi AS,D’Ombrain MC.Inflammatory caspases in innate immunity and inflammation.J Innate Immun2010;2:228-37

[52] Fantuzzi G.Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1).J Clin Immunol1999;19:1-11

[53] Kobayashi S,Bronk SF,Gores GJ.Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.Gastroenterology2005;128:2054-65

[54] Lin L,Xiao X,Cao P.Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.J Cell Mol Med2020;24:6822-32 PMCID:PMC7299726

[55] Tolksdorf B,Eberle J.Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis.J Mol Med2021;99:1279-91 PMCID:PMC8367928

[56] Abdollahi T,Abdollahi A.Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.Cancer Res2003;63:4521-6

[57] Perez LE,Shain K.Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.J Immunol2008;180:1545-55

[58] Wilson C,Johnston PG,Waugh DJ.Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.Mol Cancer Ther2008;7:2649-61

[59] Choi C,Park J,Seol DW.Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.Mol Cell Biol2002;22:724-36 PMCID:PMC133544

[60] Levina V,DeMarco R,Lokshin AE.Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.Exp Cell Res2008;314:1605-16 PMCID:PMC2386090

[61] Zhou DH,Roder C,Trauzold A.TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.Hepatobiliary Pancreat Dis Int2013;12:94-8

[62] Singha B,Gatla HR.Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells. In: Vancurova I, editor. Cytokine Bioassays. New York: Springer; 2014. pp. 295-304.

[63] Sanacora S,Chang TP.Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.Biochem Biophys Res Commun2015;460:375-9 PMCID:PMC4410072

[64] Manna S,Phyo SA.Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.J Immunol2013;191:2837-46 PMCID:PMC3750091

[65] Singha B,Manna S.Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.J Biol Chem2014;289:2687-700 PMCID:PMC3908402

[66] Chang TP,Vancurova I.Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.J Immunol2015;194:2942-53 PMCID:PMC4355060

[67] Bullenkamp J,Ayaz B.Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.Cell Death Dis2014;5:e1489 PMCID:PMC4649534

[68] Bui HTT,Le QA,Lee S.Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL.Int J Med Sci2019;16:1412-23 PMCID:PMC6818207

[69] Raman D,Hirpara JL,Pervaiz S.TRAIL sensitivity of nasopharyngeal cancer cells involves redox dependent upregulation of TMTC2 and its interaction with membrane caspase-3.Redox Biol2021;48:102193 PMCID:PMC8636823

[70] Mao ZG,Yang F,Hersey P.TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4.Apoptosis2010;15:1211-22

[71] Lamkanfi M,Saelens X,Vandenabeele P.Caspase-1 activates nuclear factor of the κ-enhancer in B cells independently of its enzymatic activity.J Biol Chem2004;279:24785-93

[72] Bergsbaken T,Cookson BT.Pyroptosis: host cell death and inflammation.Nat Rev Microbiol2009;7:99-109 PMCID:PMC2910423

[73] Nahacka Z,Peterka M.TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.Biochim Biophys Acta Mol Cell Res2018;1865:522-31

[74] Park IC,Woo SH.Tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis is dependent on activation of cysteine and serine proteases.Cytokine2001;15:166-70

[75] Ahmad M.TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.Oncogene2000;19:3363-71

[76] Mariani SM,Armandola EA.Interleukin 1β-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells.J Cell Biol1997;137:221-9 PMCID:PMC2139852

[77] Tatsuta T,Mountz JD.The prodomain of caspase-1 enhances Fas-mediated apoptosis through facilitation of caspase-8 activation.J Biol Chem2000;275:14248-54

[78] Shirley S,Micheau O.Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion.Recent Pat Anticancer Drug Discov2011;6:311-23 PMCID:PMC3204462

[79] Neumann S,Branschädel M,Scheurich P.The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.PLoS One2012;7:e42526 PMCID:PMC3420232

[80] van Roosmalen IAM, Quax WJ, Kruyt FAE. Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?.Biochem Pharmacol2014;91:447-56

[81] Jin Z,Pitti R.Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling.Cell2009;137:721-35

[82] Pop C,Green DR.Role of proteolysis in caspase-8 activation and stabilization.Biochemistry2007;46:4398-407

[83] Johnson CE.Caspase cleavage is not for everyone.Cell2008;134:720-1

[84] Békés M.The CULt of caspase-8 ubiquitination.Cell2009;137:604-6

[85] Huang K,O’Neill KL.Cleavage by caspase 8 and mitochondrial membrane association activate the BH3-only protein bid during TRAIL-induced apoptosis.J Biol Chem2016;291:11843-51 PMCID:PMC4882451

[86] Cui Z,Leonard BC,Grandis JR.Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction.Cell Death Dis2021;12:775 PMCID:PMC8346537

[87] Raulf N,Kulms D.Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.Br J Cancer2014;111:1955-64 PMCID:PMC4229641

[88] Polanski R,Polanska UM,Tang EK.Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.Cell Death Dis2015;6:e1893 PMCID:PMC4632282

[89] Granqvist V,Larsson C.Induction of interferon-β and interferon signaling by TRAIL and Smac mimetics via caspase-8 in breast cancer cells.PLoS One2021;16:e0248175 PMCID:PMC7996988

[90] Aydin C,Bisgin A.NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.BMC Cancer2010;10:584 PMCID:PMC2988028

[91] Lee KY,Jee YK.Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation.Exp Mol Med2002;34:462-8

[92] Yang TM,Fennell DA.Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.Am J Respir Cell Mol Biol2009;41:14-23 PMCID:PMC2701959

[93] Rasheduzzaman M,Park SY.Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling.Life Sci2018;208:208-20

[94] Yang J,Zhang K.Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.Biomed Pharmacother2016;84:1078-87

[95] Jeon YJ,Kim T.Correction for Jeon et al., a set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.Proc Natl Acad Sci U S A2021;118:E2113288118

[96] Geismann C,Grohmann F.TRAIL/NF-κB/CX3CL1 mediated onco-immuno crosstalk leading to TRAIL resistance of pancreatic cancer cell lines.Int J Mol Sci2018;19:1661 PMCID:PMC6032098

[97] Cingöz A,Morova T.Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.Oncogene2021;40:3201-16

[98] Kim J,Kim EO.Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers.Br J Pharmacol2016;173:1033-44 PMCID:PMC5341238

[99] Chen M,Zha D.Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.Sci Rep2016;6:35468 PMCID:PMC5067669

[100] Hinz S,Boenicke L.Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.Oncogene2000;19:5477-86

[101] Nakajima W,Tanaka N,Harada H.Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer.Cell Death Dis2014;5:e1052 PMCID:PMC3944277

[102] Azijli K,van Roosmalen I.MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.Apoptosis2013;18:851-60

[103] Unterkircher T,Vellanki SH.Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.Clin Cancer Res2011;17:4019-30